Vir Biotechnology, Inc. Price & Performance (VIR)

Vir Biotechnology shares have experienced sharp declines recently, with the stock down over 16% in the past ten days and trading near its 12-month low. Despite this, analyst price targets vary widely, signaling both skepticism and optimism. Ongoing clinical trials and regulatory momentum could influence future investor sentiment.123

Brii Biosciences reported robust cash reserves of $335.7 million and highlighted its acquisition of BRII-179 intellectual property for $18 million. The company advanced multiple Phase 2b hepatitis B studies and reduced research and administrative expenses, positioning itself for late-stage development despite increased annual losses.4

Vir Biotechnology ended 2024 with $1.1 billion in cash and investments, even as revenue declined year-over-year. The company’s expansion into immuno-oncology and late-stage infectious disease trials has attracted hedge fund interest, with analysts projecting significant long-term upside for the stock under $10.5